| FAEES | fatty acid ethyl ester synthase |
|---|---|
| FAF | fatty acid free; fibroblast-activating factor |
| FAME | fatty acid methyl ester |
| FAS | fatty acid synthetase; Federation of American Scientists; fetal alcohol syndrome |
| FE | fatty ester; fecal emesis; fetal erythroblastosis; fetal erythrocyte; fluid extract; fluorescent ery... |
| benign liver tumours | <radiology> EPITHELIAL TUMORS, nodular transformation, focal nodular hyperplasia, hepatocellular adenoma, MESENCHYMAL TUMORS, lipoma, myelolipoma, angiomyolipoma, leiomyoma, infantile haemangioendothelioma, haemangioma, benign mesothelioma, MIXED TISSUE TUMORS, mesenchymal hamartoma, benign teratoma, MISCELLANEOUS, adrenal rest tumours, pancreatic rest (12 Dec 1998) |
|---|---|
| calcified liver metastases | <radiology> Mucinous carcinoma of GI tract (colon, rectum, stomach), endocrine pancreatic carcinoma, leiomyosarcoma, osteosarcoma, malignant melanoma, papillary serous ovarian cystadenocarcinoma, lymphoma, pleural mesothelioma, neuroblastoma, breast carcinoma, medullary thyroid carcinoma, renal cell carcinoma, lung carcinoma, testicular carcinoma see: liver metastases (12 Dec 1998) |
| capsular cirrhosis of liver | Chronic perihepatitis with thickening and subsequent contraction, resulting in atrophy and deformity of the liver. Synonym: capsular cirrhosis of liver. (05 Mar 2000) |
| cardiac impression of liver | A depression on the superior area of the diaphragmatic surface of the liver corresponding to the position of the heart. Synonym: impressio cardiaca hepatis. (05 Mar 2000) |
| cardiac liver | An extensive fibrotic reaction within the liver as a result of chronic constrictive pericarditis or prolonged congestive heart failure; true cirrhosis with fibrous bridging of lobules is unusual. Synonym: cardiac liver, congestive cirrhosis, pseudocirrhosis, stasis cirrhosis. (05 Mar 2000) |
| vaccination, hepatitis a | When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. (12 Dec 1998) |
| vaccination, hepatitis b | Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection. (12 Dec 1998) |
| vaccination, infectious hepatitis | See Vaccination, hepatitis a. (12 Dec 1998) |
| vaccineation, serum hepatitis | See Vaccination, hepatitis b. (12 Dec 1998) |
| malignant liver tumours | <radiology> EPITHELIAL TUMORS, hepatocellular, hepatoblastoma (7%), hepatocellular carcinoma (HCC) (75%), cholangiocellular (6%), cholangiocarcinomarcinoma, cystadenocarcinoma, MESENCHYMAL TUMORS, tumours of blood vessels, angiosarcoma, haemangioendothelioma, other tumours, embryonal sarcoma, fibrosarcoma, TUMORS OF MUSCLE TISSUE, leiomyosarcoma, rhabdomyosarcoma, MISCELLANEOUS, carcinosarcoma, teratoma, yolk sac tumour, carcinoid, squamous carcinoma, primary lymphoma see: benign liver tumours (12 Dec 1998) |
| veno-occlusive disease of the liver | Obliterating endophlebitis of small hepatic vein radicles, described in Jamaican children, associated with ingestion of toxic plant substances in bush tea; causes ascites, which may progress to cirrhosis. (05 Mar 2000) |
| venous segments of liver | Each of the four territories of the liver separately drained by the hepatic veins. Synonym: hepatic venous segments. (05 Mar 2000) |
| giant cell hepatitis | Hepatitis in the neonatal period presumed to be due to a variety of causes, chiefly viral; characterised by direct and indirect bilirubinaemia, hepatocellular degeneration, and appearance of multinucleated giant cells; may be difficult to distinguish from biliary atresia, but is more likely to end with recovery, although cirrhosis may develop. Synonym: giant cell hepatitis. (05 Mar 2000) |
| cavernous haemangioma of liver | <radiology> Ultrasound: increased echogenicity, CT: decreased density, enhances from periphery, becomes isodense, may enlarge during pregnancy, in kids: most common benign liver tumour, increased morbidity/mortality, classic triad: hepatomegaly, cut. Haemangiomas, congestive heart failure, with or without liver bruit, may rupture leading to haemoperitoneum, may regress spontaneously (as may haemangioendothelioma) (12 Dec 1998) |
| viral hepatitis | Liver inflammation caused by viruses. Specific hepatitis viruses have been labelled a, b, c, d, e, f, and g. While other viruses can also cause hepatitis, their primary target is not the liver. (12 Dec 1998) |